🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Wall Street Opens Higher on Hopes of Later Tapering; Dow up 190 Pts

Published 08/23/2021, 09:25 AM
Updated 08/23/2021, 09:43 AM
© Reuters
US500
-
DJI
-
CVX
-
NVDA
-
PFE
-
AMD
-
IXIC
-
TRIL
-
TCEHY
-
JD
-
BABA
-
BTC/USD
-
UBER
-
LYFT
-
COIN
-
DIDIY
-

By Geoffrey Smith 

Investing.com -- U.S. stock markets opened higher on Monday, supported by hopes that the Federal Reserve may put off tapering its asset purchases until at least December amid signs that the latest global wave of Covid-19 is slowing the global economic recovery. 

By 9:35 AM ET (1335 GMT), the Dow Jones Industrial Average was up 194 points, or 0.6%, at 35,314 points, while the S&P 500 and the Nasdaq Composite were both up 0.5%.

Sentiment was also lifted by China's announcement on Monday that it had not registered any Covid-19 cases through community spread for the first time since July. The heavy-handed reaction to localized outbreaks of the coronavirus in China has hit global oil demand and led to a fresh round of disruptions of global supply chains, notably through capacity restrictions at the country's ports. 

The supply squeeze has been sharpest in sectors such as semiconductors, and these again stood out in early trading, with Nvidia (NASDAQ:NVDA) stock rising 2.6% and Advanced Micro Devices (NASDAQ:AMD) stock rising 2.3%. 

Elsewhere, Uber (NYSE:UBER) stock quickly shook off the disappointment of a Friday court ruling in California that struck down its exemption from a new law that stands to raise its operating costs substantially. The court ruled the Proposition 22 - which allows the likes of Uber, Lyft (NASDAQ:LYFT) and Doordash to pay their drivers as contractors rather than employees - is unconstitutional. Uber said it plans to appeal. 

After losing as much as 5% in premarket, Uber stock was up 0.1% while Lyft stock was down only 0.4%. DoorDash stock was down 1.8%.

Vaccine stocks were in demand again, with Pfizer (NYSE:PFE) stock rising 2.7% and BioNTech stock rising 9.5% after the U.S. Food and Drug Administration gave their Covid-19 drug full approval for use by people over 16, upgrading the Emergency Use Authorization that had previously been in place. The vaccine's new status affords greater legal protection to companies who impose vaccine mandates on their staff ( Chevron (NYSE:CVX) became the latest to do so on Monday), and is perceived as helping to boost confidence in the drug more broadly. 

Pfizer stock was also supported by news that it will buy out the rest of smaller biotech company Trillium Therapeutics (NASDAQ:TRIL) at a valuation of $2.6 billion, news that almost tripled Trillium's stock price.

Elsewhere, Coinbase (NASDAQ:COIN) stock rose 2.6% while other cryptocurrency proxies made larger gains as Bitcoin rallied back above $50,000. 

Chinese ADRs continued to underperform, however, as U.S.-based investors continued dumping them in anticipation of regulatory actions from both Beijing and Washington. Alibaba ADRs (NYSE:BABA) fell 2.6% and Didi Global ADRs (NYSE:DIDI) fell 2.7%, while Tencent ADRs (OTC:TCEHY) eked out a gain of only 0.4%. JD.com ADRs (NASDAQ:JD) were essentially flat after posting second-quarter results that showed a marked drop in profit despite revenue growth of over 25%.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.